Bromelain is a crude extract that comes from pineapples, particularly the stems or immature fruits; thus Bromelain is sometimes referred to as Pineapple extract.
Proteinase Inhibitors, such as Cystatin
The overall mixture of Bromelain tends to have enzymatic activity on analyl, glycyl, and leucyl bonds and has a broad enzymatic profile.
Bromelain is usually produced by cooling pineapple juice and then subjecting it to centrifugation, ultrafiltration and lyophilization. Alpha-macroglobulin is usually added to aqueous solutions, as Bromelain can self-digest in solution. However, extraction can feasibly come from other sections of the pineapple such as the peels and rind.
The final product is a yellowish powder which retains the aromatic properties of pineapples.
Bromelain appears to be absorbed from the intestines and is bioactive. It is absorbed enzymatically active in the intestines of man at around 40% with a half-life of around 6-9 hours. Oral bioavailability of bromelain has been replicated elsewhere.
Circulating concentrations of 5000pg/mL enzymatically active bromelain have been noted in vivo 48 hours after oral ingestion of 8.6g Bromelain. An AUC of 2.5-4mcg bromelain is estimated between 3-51 hours after 8.6g orally ingested.
While circulating in serum, Bromelain associates with the anti-proteinases alpha-2-macroglobulin and antichymotrypain. Binding to these anti-proteinases reduces the enzymatic activity of bromelain, but does not abolish it.
Despite being a quaternary protein in size, Bromelain appears to be absorbed and enzymatically active.
The general idea of Bromelain and digestion, as well as the entire protease class, is that they may contribute for an otherwise impaired digestive system. Bromelain has some other effects extending beyond its activities as a protease, however.
Bromelain has been shown effective in reducing dyspepsia in persons without heliobactor pylori infections when in conjunction with other nutraceuticals.
Via its protease activities, bromelain can slow down intestinal motility in rats and in vitro. Its activities are inhibited by PAR-2 (receptor sensitive to proteases) as well as PDE4 and PLC downstream of the receptor, suggesting mechanisms of action.
An oral dose of 2-20mg bromelain in drinking water once daily is able to reduce inflammation in a murine model of colonic inflammation, and theoretically may aid inflammatory bowel disease (IBD). Controlled doses of 2mg and 5mg showed benefit, although 2mg was too low to be significantly different than control.
Bromelain, in vitro, can straight up remove (possibly through digesting) select receptors on T-cells; CD6-8, CD44 and an isoform of CD45, Leu8/LAM1 and E2/MIC2 are removed from T-cells after incubation with Bromelain. CD2-3 and CD28 were confirmed to be unaffected. Vicariously through these receptor changes, Bromelain can increase CD2 expression (normally hindered by CD44) and increase T-cell binding to monocytes via CD2 and via mechanisms not mediated by receptors the former of which are due to CD44 elimination. Bromelain has previously been shown to enhance T-cell binding to autologous E rosettes and is also implicated in CD36 elimination from macrophages, reducing formation of foam cells.
Elimination of the receptor proteins CD128a/CXCR1 and CD128b/CXCR2, receptors for IL-8 and related molecules, also occurs after Bromelain incubation. Elimination of these receptors in particular causes less neutrophil recruitment to the site of inflammation by reducing chemokine signalling efficacy.
Bromelain also appears to inhibit signal transduction in T0 cells that results in inhibition of ERK2 phosphorylation and p21ras activation and can inhibit the COX2 enzyme as well as reduce activation of NF-kB.
In general, it appears Bromelain eliminates the receptors on immune cells that respond to (mostly) pro-inflammatory signals. Without this needed junction in signalling, pro-inflammation doesn't occur as much and a relative state of anti-inflammation appears to occur.
Doses in rats around 10mg/kg bodyweight appear to be approximately as effective as dexamethasone in some studies and other animal or in vitro studies compare its potency against standard NSAID treatment (aspirin, diclofenac) with similar potencies.
One study conducted with protease supplementation (Bromelain and Papain) found that protease enzymes circulating in serum were able to attenuate muscle damage associated with exercise and preserve power output over time. These effects have been noted before with protease supplementation in general, and seems to be more due to that property rather than Bromelain per se. Protections seems to be confered against ischemia-reperfusion injury as well, although the study in question here is confounded with trypsin and rutin ingestion.
Preliminary research suggests it can reduce markers of muscle breakdown and soreness, while preserving power output. Possibly a good idea for sports athletes, although it might have to be pre-loaded
An in vitro study investigating the immunomodulatory effect of Bromelain noted that Bromelain was able to reduce the inflammatory insult on Pancreatic Beta-cells, and hypothesized that Bromelain could aid Type 1 Diabetes. Subsequently, one small study investigated whether protease supplementation was able to reduce the risk of developing Type 1 Diabetes Mellitus (TIDM) in a population of persons who tested positive for antibodies that put them at risk for TIDM was conducted. A daily dose of 90mg bromelain (with 100mg rutinoside and 48mg trypsin) showed positive biochemical changes in immune status but did not significantly affect rate of Type 1 Diabetes development over 8 years (24 months of supplementation) in these 20 persosn.
Bromelain possesses both fibrolytic and anti-platelet functioning, .
When looking at Bromelain in vitro, it appears to reduce both platelet aggregation as well as binding of platelets to endothelium via its enzymatic components. Bromelain is effective at inhibiting 6-11% of thrombus formation at an oral dose of 60mg/kg bodyweight in rat mesenteric vessels. The fibrolytic functions are also tied in with enzymatic activity, and the two confer protective effects from atherosclerosis.
According to a Meta-Analysis of 223 studies, 3 interventions have been conducted in rats investigating cardiovascular protection from Bromelain; these studies varied in research goals investigating platelet adhesion, Akt/FOXO protection from ischemia, and allograph atherosclerosis. Although all studies showed benefit with Bromelain supplementation with no apparent side effects, their measures and research goals varied too widely to be harmonized.
The same Meta-Analysis found 4 human trials investigating Bromelain and Cardiovascular health, one of which is not indexed online and is in German. The studies showed promise, but had low internal validity; only one was double blinded and placebo controlled.
Bromelain appears to have the ability to prevent macrophages (an immune cell) from turning into foam cells via eliminating the CD36 receptor. Foam cells are pro-atherogenic immune cells which contribute to arterial plaque formation.
Overall, Bromelain has many mechanisms which suggest it can be quite a heart healthy compound; mostly acting in blood vessels rather than cardiac tissue. The studies conducted on humans, however, are of lesser quality and have not since been replicated
Beta-amyloid is a protein known as the 'age pigment' due to its association with aging; it is suspected of contributing to Alzheimer's Disease.
After oral ingestion, bromelain is complexed with Macroglobulin. This complex appears to be able to degrade beta-amyloid pigmentation while Macroglobulin complexes with intrinsically produced proteins are ineffective. This is a mechanism by which Bromelain may offer neuroprotection.
Interventions into neuroprotection and Bromelain have been less promising. One intervention looking at protease supplementation and Multiple Sclerosis found no significant treatment effects of oral protease enzymes.
Bromelain from Pineapple Stem (stem bromelain) has been shown to inhibit adipogenesis in vitro using 3T3-L1 adipocytes. A dose-dependent suppression of triglyceride accumulation was seen up to 50ug/mL enzymatically active bromelain, in where the effects were saturated; enzymatically inactive bromelain was ineffective. There was about 25% less triglycerides after treatment at this level over the 8 days of incubation, and was 30% more potent than all-trans retinoic acid and 1,25-dihydroxycalciferol.
It seems to inhibit mid and late phase adipogenesis, as mRNA of C/EBPβ and C/EBPδ as well as mitotic clonal expansion are unaffected yet mRNA C/EBPα and PPARγ are suppressed, more than halfing their relative mRNA levels. This inhibition of mid to late phase adipogenesis shows in late stage markers of adipocyte differentiation, as the proteins Lipoprotein Lipase (LPL), aP2, Fatty acid Synthase (FAS) and CD36 are all markedly reduced. A downregulation of perilipin in these cells remained during maturation, and this inhibition stays even if bromelain is removed from the medium during late-phase differentiation.
PPARγ appears to have reduced phosphorylation via Akt, although Akt phorphorylation per se is unaffected. TNF-α being increased may also contribute.
Apoptosis of mature cells was seen as increasingly dose-dependent with minimal effects at 10ug/mL, moderate effects at the inhibitory saturation point of 50ugmL, and significnat apoptosis at 100ug/mL.
A single but sexy in vitro study; too soon to draw any conclusions, but it looks quite interesting
Bromelain may reduce complications with acute sinusitis known as a 'stuffed nose' to a greater extent than placebo. One study conducted noted that 83% of persons using bromelain had reductions in nasal inflammation as compared to 52% of the placebo. Bromelain appears to reduce the length it takes to alleviate sinusitis significantly, yet combining bromelain with traditional therapy for sinusitis appears to reduce the efficacy of both.
Might clear your nose if you have the sniffles
Bromelain appears to have the ability to increase bioavailability (percent absorbed) and reduce the side-effects associated with anti-biotics such as penicillins and tetracyclins after oral administration. When looking into Bromelain and other compounds, it appears that a general motif of protease compounds (especially Bromelain) allowing larger molecules to pass through the intestines easier. This has been shown with a 6.7-fold increase in the bioavailability of low-molecular weight heparin, flurescein, and reduced glutathione. It's interactions on bioavailability with tetracycline are not clear, as one study found an increase in bioavailability yet another did not.
Phlogenzym is a brand name product consisting of Bromelain at 90mg, trypsin at 48mg and rutoside trihydrate at 100mg; usually adminstered in an enteric capsule. Several studies use this blend of enzymes rather than isolated Bromelain.
The most well known ability of pineapples (despite bromelain's abilities against inflammation, digestion, and pharmacokinetic profile of being a blood borne active enzyme; a possibility that was once thought impossible) is the fact that pineapples flavor semen...
The volatile components in pineapple that may contribute to flavor and aroma include a series of beta-hydroxy esters such as methyl beta-hydroxyoctanoates and hexanoates (although in isolation their smell is reported repulsive, suggesting they contribute to the taste) and octalactones, which 'express the coconut-like smell of other lactones'. Other compounds that are suspect are methyl butanoates that, along with methyl hexanoate, comprise over 74% of total volatiles. It is likely that some of these compounds may flavor semen.
There are no clinical trials into isolated the compound(s) that flavor semen, unfortunately.
Side-effects with moderate to higher dosages (400-800mg) tend to be gastrointestinal in nature, including pasty feces and farting. Oral administration of 500mg/kg bodyweight in rats does not seem to be associated with general side-effects.
After an attempted oral toxicity test in animals, no deaths could be seen with dosages up to 10g/kg bodyweight in rats, mice, or rabbits.
Lethal doses of injections were 37mg/kg in mice and 85mg/kg in rats.